Firefly Neuroscience (AIFF) Asset Writedowns and Impairment (2011 - 2025)

Firefly Neuroscience (AIFF) posted Asset Writedowns and Impairment of $99000.0 for Q4 2025, down 34.87% on a QoQ basis from $152000.0 in Q3 2025.

Analysis

Firefly Neuroscience (AIFF) Asset Writedowns and Impairment (2011 - 2025) Analysis & Trends

Firefly Neuroscience has reported Asset Writedowns and Impairment for 7 years, with the latest figure at $99000.0 in Q4 2025.

On a quarterly basis, Asset Writedowns and Impairment changed N/A year-over-year to $99000.0 in Q4 2025; TTM through Dec 2025 was $251000.0, a N/A change from a year earlier, with the FY2025 full-year figure at $251000.0, down 71.28% from the prior year.
Asset Writedowns and Impairment was $99000.0 for Q4 2025 at Firefly Neuroscience, down from $152000.0 in the prior quarter.
The five-year high for Asset Writedowns and Impairment was $152000.0 in Q3 2025, with the low at $99000.0 in Q4 2025.

Peer Set

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)
1	GE HealthCare Technologies	31.10 Bn	29.22 Bn	2.18 Bn
2	Lantheus Holdings	6.59 Bn	6.00 Bn	241.86 Mn
3	Heartflow	4.24 Bn	3.87 Bn	53.19 Mn
4	Neogen	2.58 Bn	2.39 Bn	107.80 Mn
5	Butterfly Network	1.75 Bn	1.62 Bn	23.29 Mn
6	QuidelOrtho	954.15 Mn	830.75 Mn	-
7	Ceribell	944.88 Mn	815.62 Mn	25.94 Mn
8	Anbio Biotechnology	941.05 Mn	929.15 Mn	-
9	Varex Imaging	780.16 Mn	694.86 Mn	76.70 Mn
10	Firefly Neuroscience	23.25 Mn	14.03 Mn	253,000.00

Historic Data

Download Data